hfd

Lansoprazole (A-65006) is a 2, 2, 2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)

PTUPB is a potent dual inhibitor of sEH and COX-2 enzymes with IC50 values of 0.9 nM and 1.26 μM, respectively.

ACH-000143 have been identified as a novel agonist of the melatonin receptors MT1 and MT2.

Ketoprofen (RP-19583) is a propionic acid derivative and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. It inhibits cyclo-oxygenase I and II, decreasing the formation of prostaglandin and thromboxane precursors. This reduction in prostaglandin synthesis, mediated by prostaglandin synthase, is responsible for its therapeutic effects. Additionally, Ketoprofen decreases thromboxane A2 formation via thromboxane synthase, inhibiting platelet aggregation.

SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.

Lycorine (Narcissine) inhibits protein synthesis and may inhibit ascorbic acid biosynthesis, although studies on the latter are controversial and inconclusive.

BVT 2733 is a new, non-steroidal, isoform-specific inhibitor of 11β-HSD1.

MTHFD2-IN-5 (Compound 16e) is a selective inhibitor of MTHFD2 with an IC50 of 66 nM. It inhibits the proliferation of MOLM-14 cells with a GI50 of 720 nM and demonstrates antitumor activity in mouse models.

MTHFD2-IN-6 (compound 41) is a potent and selective inhibitor of MTHFD2, displaying inhibitory activity against both MTHFD1 and MTHFD2 with IC50 values of 19.05 μM and 1.46 μM respectively.

MTHFD2-IN-1 (compound 12) is a potent inhibitor of methylenetetrahydrofolate dehydrogenase (MTHFD2) [1].

MTHFD2-IN-2 (compound 13) is a potent inhibitor of methylenetetrahydrofolate dehydrogenase (MTHFD2) [1].

MTHFD2-IN-3 (compound 10), a potent inhibitor of methylenetetrahydrofolate dehydrogenase (MTHFD2), demonstrates significant efficacy in obstructing the activity of this enzyme [1].

MTHFD2-IN-4, a tricyclic coumarin derivative, serves as a potent inhibitor of MTHFD2 and has applications in cancer research [1].

MTHFD2-IN-4 sodium, a potent inhibitor of MTHFD2 and a tricyclic coumarin derivative, is applicable in cancer research [1].

IKFQFHFD is a pH-responsive self-assembling peptide. It exhibits biocompatibility at neutral pH and adopts an antimicrobial peptide-like molecular structure only at acidic pH. IKFQFHFD can be used to treat chronic wounds caused by biofilm infections, such as venous ulcers, diabetic ulcers, and pressure sores.

DS18561882 is an orally available, selective and potent inhibitor of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) with antitumor activity, inhibits MTHFD1 activity and can be used in the study of breast cancer.

TH9028 TFA is an effective MTHFD2 inhibitor (IC50=11 nM) that suppresses proliferation in HL-60 cells, AML cells, and T-ALL Jurkat cells.

LY 345899 is a folate analog that inhibits methylenetetrahydrofolate dehydrogenase and MTHFD2, with IC50 values of 96 nM and 663 nM, respectively, and a Ki of 18 nM for MTHFD1.

TH9028 is an inhibitor of MTHFD2, featuring an IC50 value of 11 nM. It demonstrates specific inhibitory activity with IC50 values of 7.97 nM, 27 nM, and 0.5 nM against hMTHFD2, MTHFD2L, and MTHFD1, respectively.

Emofolin sodium is the sodium salt of a synthetic antimetabolite analogue of folate with antineoplastic activity,which competes for the folate binding site of the enzyme dihydrofolate reductase, resulting in inhibition of tetrahydrofolate synthesis, deple

10 FTHF disodium (10-Formyltetrahydrofolic acid disodium) is a form of tetrahydrofolate, a formyl donor in anabolism, involved in the synthesis of purine compounds.

KPLH1130, a specific pyruvate dehydrogenase kinase (PDK) inhibitor, enhances glucose tolerance in mice fed a high-fat diet (HFD). It effectively hinders macrophage polarization and mitigates proinflammatory reactions.

Mahanimbine is found in the roots, leaves and stems of Murraya koenigii and is an orally active alkaloid extracted from Murraya koenigii. Bifidobacterium bifidum leaves on histopathological changes in pancreatic beta cells of streptozotocin-induced diabetic rats.

FXR agonist9 (compound 26) is a selective, orally active partial agonist of FXR with an EC50 of 0.09 µM (maximum efficacy of 75.13%). It ameliorates the pathological features of fatty liver disease in mice induced by HFD and CCl4-related metabolic dysfunction.